Remove Licensing Remove Marketing Remove Vaccine
article thumbnail

Nobel Prize celebrates AI’s role in protein structure innovation

Drug Target Review

Baker’s model could revolutionise drug development, synthetic biology, and nanotechnology, opening possibilities for new medical treatments, vaccines, nanomaterials, and sensors. With these exclusive rights, they can establish a competitive edge, control market entry, and potentially set higher prices due to the lack of competition.

article thumbnail

Takeda to seek approval of new kind of narcolepsy drug after study data

BioPharma Drive: Drug Pricing

Published July 14, 2025 Ben Fidler Senior Editor post share post print email license Takeda reported positive results for oveporexton, a drug being developed for narcolepsy Type 1, on July 14, 2025. The drug, formerly known as TAK-861 but now called oveporexton, was evaluated in two Phase 3 studies in a main type of narcolepsy.

Drugs 280
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Navigating Regulatory Hurdles in Drug Development

DrugBank

A well-known example is Merck’s rofecoxib , approved for pain relief in 1999 but withdrawn from the market in 2004 due to cardiovascular risks that were not sufficiently monitored during post-market surveillance. This means pharmaceutical companies must remain vigilant and adaptable to comply with evolving regulations.

article thumbnail

FDA clears Nuvation lung cancer drug, setting up battle with Bristol Myers and Roche

BioPharma Drive: Drug Pricing

Published June 11, 2025 Ben Fidler Senior Editor post share post print email license The FDA on June 11, 2025 approved Nuvation's Ibtrozi for ROS1-positive non-small cell lung cancer. In a research note on Wednesday, RBC Capital Markets analyst Leonid Timashev estimated peak yearly sales of the drug could reach nearly $640 million.

FDA 270
article thumbnail

Vor, with new CEO, changes course to target autoimmune disease

BioPharma Drive: Drug Pricing

Published June 26, 2025 Gwendolyn Wu Senior reporter post share post print email license B cells, like those pictured above, malfunction in autoimmune disease. Vor Biopharma licensed a drug in June 2025 that targets proteins essential to B cell survival. and European drugmakers.

Disease 109
article thumbnail

Moderna COVID vaccine gets full approval for children

BioPharma Drive: Drug Pricing

Deep Dive Library Events Press Releases Topics Sign up Search Sign up Search Pharma Biotech FDA Clinical Trials Deals Drug Pricing Gene Therapy An article from Dive Brief Moderna COVID vaccine gets full approval for children The approval comes amid regulatory upheaval under HHS head Robert F. Kennedy Jr., Kennedy Jr.

Vaccine 231
article thumbnail

Soleno sales of new Prader-Willi drug rise faster than expected

BioPharma Drive: Drug Pricing

Published July 10, 2025 Ben Fidler Senior Editor post share post print email license Soleno Therapeutics on July 10, 2025 announced preliminary sales for its new Prader-Willi Syndrome drug Vykat. Until Vykat came along, though, no drug therapies were specifically approved to curb the all-consuming hunger that hallmarks the condition.

Drugs 243